Literature DB >> 7536741

Cell type-specific transactivation of the VCAM-1 promoter through an NF-kappa B enhancer motif.

M Ahmad1, N Marui, R W Alexander, R M Medford.   

Abstract

Cytokine activation of vascular cell adhesion molecule-1 (VCAM-1) gene expression by endothelial cells is an important feature in a variety of vascular inflammatory responses. Cytokines transcriptionally activate the VCAM-1 promoter in endothelial cells at least in part through two closely linked NF-kappa B enhancer motifs, kappa L-kappa R (positions -77 and -63). However, cytokine activation of the dimeric NF-kappa B transcriptional factor (p50+p65 subunits) occurs in almost all cell types, whereas VCAM-1 gene expression exhibits a cell type-specific pattern of expression. Tumor necrosis factor-alpha markedly transactivated a transiently transfected minimal kappa L-kappa R motif-driven VCAM-1 promoter, p85VCAMCAT, in passaged human vascular endothelial cells but not in the human epithelial cell line, HeLa suggesting that cell type-specific factors may function through the kappa L-kappa R motif. Both cell types exhibited similar inductions of NF-kappa DNA binding activity and transcriptional activity. However, co-transfection of HeLa cells with p65 and p50 expression vectors demonstrated that the minimal VCAM-1 promoter was effectively transactivated by p65 alone but that additional co-expression of p50 blocked this activity. Furthermore, cytokine activation of the minimal VCAM-1 promoter in HeLa cells was recovered by inhibition of p50 expression using antisense oligonucleotide. These studies suggest that the NF-kappa B(p50+p65 heterodimer) does not support transactivation of the VCAM-1 promoter with the p50 subunit potentially playing a significant inhibitory role in suppressing cytokine activation of VCAM-1. In addition, p65 associated transcriptional factors other than NF-kappa B may serve as positive, cytokine-inducible, cell type-specific regulators of VCAM-1 gene expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536741     DOI: 10.1074/jbc.270.15.8976

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Flow-mediated endothelial mechanotransduction.

Authors:  P F Davies
Journal:  Physiol Rev       Date:  1995-07       Impact factor: 37.312

2.  Activation of RelA homodimers by tumour necrosis factor alpha: a possible transcriptional activator in human vascular endothelial cells.

Authors:  Nobuyuki Marui; Russell M Medford; Mushtaq Ahmad
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

3.  Utilization of IκB-EGFP Chimeric Gene as an Indicator to Identify Microbial Metabolites with NF-κB Inhibitor Activity.

Authors:  Yu-Ling Lin; Yen-Shun Chen; Jui-Hung Hsieh; Ching-Min Lin; Hsin-Yi Wu; Chen-Si Lin; Rea-Min Chu; Kuang-Wen Liao; Yuan-Hsun Hsu
Journal:  Biol Proced Online       Date:  2010-10-02       Impact factor: 3.244

4.  Involvement of Egr-1/RelA synergy in distinguishing T cell activation from tumor necrosis factor-alpha-induced NF-kappa B1 transcription.

Authors:  P C Cogswell; M W Mayo; A S Baldwin
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

Review 5.  Endothelial activation: intracellular signaling pathways.

Authors:  Jordan S Pober
Journal:  Arthritis Res       Date:  2002-05-09

6.  Interferon enhances tumor necrosis factor-induced vascular cell adhesion molecule 1 (CD106) expression in human endothelial cells by an interferon-related factor 1-dependent pathway.

Authors:  S Lechleitner; J Gille; D R Johnson; P Petzelbauer
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

7.  Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation.

Authors:  L Yang; L Cohn; D H Zhang; R Homer; A Ray; P Ray
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

8.  Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2.

Authors:  Chen Wang; Lingfeng Qin; Thomas D Manes; Nancy C Kirkiles-Smith; George Tellides; Jordan S Pober
Journal:  J Exp Med       Date:  2014-02-10       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.